Gus M. Bilirakis sold Merck & Company Inc (NYSE: MRK)
Gus M. Bilirakis (R-FL), a U.S. Representative, has disclosed 1 trade in Merck & Company Inc (MRK) since 2021, a single sale, worth an estimated $33K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a sale: Gus M. Bilirakis sold $15,001 - $50,000 of Merck & Company Inc (NYSE: MRK) on October 8, 2021. Since that trade, MRK is up +83.81% against the S&P 500 up +82.53%, an outperformance of +1.28%.
Data updated
Gus M. Bilirakis's MRK trades vs the price
MRK is up +83.81% since Gus M. Bilirakis sold on October 8, 2021, versus +82.53% for the S&P 500.
Performance since this trade
All Gus M. Bilirakis MRK trades
Gus M. Bilirakis & MRK trading FAQ
Is it legal for Gus M. Bilirakis to trade Merck & Company Inc (MRK) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Merck & Company Inc (MRK), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. BullishWhales tracks those disclosures; this page does not imply the trade was improper.
When did Gus M. Bilirakis sell MRK?
Gus M. Bilirakis disclosed a sale of $15,001 - $50,000 of Merck & Company Inc (MRK) on October 8, 2021, according to public STOCK Act filings.
How has MRK performed since Gus M. Bilirakis's trade?
Since Gus M. Bilirakis sold MRK on October 8, 2021, the stock is up +83.81%, versus +82.53% for the S&P 500 over the same period, an outperformance of +1.28%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional MRK trades?
BullishWhales tracks every disclosed congressional trade in Merck & Company Inc (MRK) on the Merck & Company Inc congressional trading page, which aggregates filings across all members of Congress.
Gus M. Bilirakis's MRK tradesAll congressional filings for Merck & Company IncGus M. Bilirakis's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.